Snapshot from Sep 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

FDA Authorizes Abbott Libre Duo 10 Day

Analysis based on 25 articles · First reported Aug 25, 2026 · Last updated Aug 28, 2026

Sentiment
70
Attention
4
Articles
25
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The FDA authorization strengthens Abbott's leadership in diabetes technology, potentially boosting sales of its Libre portfolio and expanding its total addressable market. Competitors in the continuous glucose monitoring and insulin pump space may face increased pressure to innovate, while the approval could accelerate adoption of continuous ketone monitoring as a new standard of care.

Medical Devices Diabetes Care Digital Health

The U.S. United States — Food and Drug Administration (FDA) authorized Abbott Laboratories' Libre Duo 10 Day system, the world's first dual glucose-ketone sensing biowearable for people with diabetes. The device continuously monitors both glucose and ketone levels, alerting users to rising ketones that could lead to diabetic ketoacidosis (DKA), a serious complication. It received De Novo authorization after a breakthrough device designation, and is the first to meet the FDA's integrated continuous glucose monitoring (iCGM) and integrated continuous glucose and ketone monitoring (iCGK) standards. Abbott plans to launch the device in the U.S. later this year. The system integrates with Abbott's Libre digital health ecosystem and is designed for compatibility with automated insulin delivery systems from Beta Bionics, Insulet, Medtronic (MiniMed), Sequel Med Tech, and Tandem Diabetes Care. Abbott also recently partnered with Alphabet Inc. — Google Health to bring glucose monitoring and AI-driven guidance to the Alphabet Inc. — Google Health app.

75 Abbott Laboratories received CE Mark
55 Abbott Laboratories partnered with pump makers
stock
Abbott is the developer and manufacturer of the Libre Duo 10 Day system, receiving FDA authorization for the world's first dual glucose-ketone sensor. This approval strengthens its diabetes care franchise and is expected to drive future revenue growth.
Importance 100.0 Sentiment 80.0
govactor
The FDA granted De Novo authorization to Abbott's device, establishing new regulatory standards for continuous ketone monitoring. This action expands the regulatory framework for diabetes technology.
Importance 90.0 Sentiment 0.0
priv
Beta Bionics is collaborating with Abbott to integrate its iLet automated insulin delivery system with the Libre Duo sensor, expected by end of 2026. This partnership enhances its product ecosystem.
Importance 40.0 Sentiment 60.0
stock
Insulet is working with Abbott to enable compatibility between its insulin delivery devices and the Libre Duo sensor, planned for 2027. This integration could expand its market reach.
Importance 40.0 Sentiment 60.0
stock
Medtronic's MiniMed is collaborating on an exclusive integration with Abbott's dual glucose-ketone sensors, expected in 2027. This partnership may enhance its smart dosing systems.
Importance 40.0 Sentiment 60.0
priv
Sequel Med Tech is partnering with Abbott to integrate its twiist AID system with the Libre Duo sensor, expected by end of 2026. This collaboration supports its product development.
Importance 40.0 Sentiment 60.0
stock
Tandem is working with Abbott to enable compatibility with its insulin pumps, planned for 2027. This integration could broaden its device compatibility.
Importance 40.0 Sentiment 60.0
subs
Alphabet Inc. — Google Health recently entered a multi-year collaboration with Abbott to bring glucose monitoring and AI-driven health guidance to its app, complementing the Libre Duo launch.
Importance 30.0 Sentiment 50.0
ngo
The American Diabetes Association provides clinical guidance on DKA and ketone testing, referenced in the context of the device's importance. It is not directly impacted.
Importance 20.0 Sentiment 0.0
ngo
Breakthrough T1D, a diabetes advocacy organization, expressed support for the new technology, highlighting its potential to prevent DKA. Its CEO commented on the device's benefits.
Importance 20.0 Sentiment 0.0
per
Chris Scoggins, executive vice president of Abbott's diabetes care business, is a spokesperson for the device, explaining its features and benefits.
Importance 15.0 Sentiment 0.0
per
Jennifer Sherr, a pediatric endocrinologist at Yale School of Medicine, provided expert commentary on the clinical value of continuous ketone monitoring.
Importance 10.0 Sentiment 0.0
per
Aaron J. Kowalski, CEO of Breakthrough T1D, expressed support for the device, emphasizing its potential to prevent DKA complications.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.